Aethlon Medical Inc., a medical therapeutic company focused on developing products for cancer and life-threatening infectious diseases, has announced the publication of preclinical data showcasing the Hemopurifier®'s ability to remove platelet-derived extracellular vesicles (PD-EVs) from plasma. This breakthrough supports their ongoing oncology clinical trial in Australia, as PD-EVs are known to contribute to the spread of cancer. The study, published on bioRxiv, highlights the Hemopurifier's potential across multiple indications, suggesting a "pipeline within a device" approach for future therapeutic applications. Aethlon Medical plans to submit these findings to a peer-reviewed journal and further investigate PD-EV removal in diseases of interest.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。